Mitral Transcatheter Edge-to-Edge Repair in INTERMACS 3-4 Profile Patients with Severe Mitral Regurgitation

Overview

Journal J Cardiovasc Dev Dis

Specialty Cardiology & Vascular Diseases

Date 2024 Nov 26

PMID 39590216

Authors

Simone Frea

Stefano Pidello

Filippo Angelini

Paolo Boretto

Pier Paolo Bocchino

Daniele Melis

Giuseppe Giannino

Elena Cavallone

Francesca Giordana

Sara Rettegno

Carol Gravinese

Giulia De Lio

Guglielmo Gallone

Veronica Dusi

Gianluca Alunni

Antonio Montefusco

Fabrizio DAscenzo

Massimo Boffini

Claudia Raineri

Mauro Rinaldi

Gaetano Maria De Ferrari

Affiliations

Soon will be listed here.

Abstract

Background: Heart transplantation and left ventricular assist device (LVAD) implementation are effective treatments for advanced heart failure (HF), although their use is limited by organ availability and the high incidence of adverse events. The efficacy of mitral transcatheter edge-to-edge repair (TEER) as a bridge to transplantation or as a destination therapy in advanced HF is still debated.

Methods: A total of 63 patients with INTERMACS class 3 or 4 with contraindications for LVAD and severe functional mitral regurgitation (FMR) were evaluated for TEER implantation eligibility. The primary endpoint was a composite of death, urgent heart transplantation and LVAD implantation at 12 months.

Results: A total of 36 patients underwent TEER, while 27 patients received optimal medical therapy (MT) alone. In the intervention group, 35 patients (97%) were discharged alive. In the MT group, two in-hospital deaths occurred, two patients underwent urgent heart transplantation, and three patients were discharged on inotropes. At the 12-month follow-up, the incidence of the primary endpoint occurring was lower in the TEER group (25% vs. 70%, HR 0.25, 95% CI 0.11-0.60, < 0.01) and the tolerance to neurohormonal therapy was higher (53% vs. 30%, = 0.03).

Conclusions: In advanced HF patients with INTERMACS profile 3 or 4 and severe FMR, TEER on top of optimal MT was associated with a lower incidence of death, urgent heart transplantation or LVAD implantation at 12 months compared to optimal MT alone.

References

Chioncel O, Mebazaa A, Maggioni A, Harjola V, Rosano G, Laroche C . Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2019; 21(11):1338-1352. DOI: 10.1002/ejhf.1492. View

Zoghbi W, Enriquez-Sarano M, Foster E, Grayburn P, Kraft C, Levine R . Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003; 16(7):777-802. DOI: 10.1016/S0894-7317(03)00335-3. View

Frea S, Pidello S, Canavosio F, Bovolo V, Botta M, Bergerone S . Clinical assessment of hypoperfusion in acute heart failure – evergreen or antique?. Circ J. 2015; 79(2):398-405. DOI: 10.1253/circj.CJ-14-1052. View

Stone G, Lindenfeld J, Abraham W, Kar S, Lim D, Mishell J . Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. 2018; 379(24):2307-2318. DOI: 10.1056/NEJMoa1806640. View

Frea S, Bovolo V, Bergerone S, DAscenzo F, Antolini M, Capriolo M . Echocardiographic evaluation of right ventricular stroke work index in advanced heart failure: a new index?. J Card Fail. 2012; 18(12):886-93. DOI: 10.1016/j.cardfail.2012.10.018. View

Cook J, Colvin M, Francis G, Grady K, Hoffman T, Jessup M . Recommendations for the Use of Mechanical Circulatory Support: Ambulatory and Community Patient Care: A Scientific Statement From the American Heart Association. Circulation. 2017; 135(25):e1145-e1158. DOI: 10.1161/CIR.0000000000000507. View

Giannino G, Braia V, Griffith Brookles C, Giacobbe F, DAscenzo F, Angelini F . The Intrinsic Cardiac Nervous System: From Pathophysiology to Therapeutic Implications. Biology (Basel). 2024; 13(2). PMC: 10887082. DOI: 10.3390/biology13020105. View

DAscenzo F, Moretti C, Grosso Marra W, Montefusco A, Omede P, Taha S . Meta-analysis of the usefulness of Mitraclip in patients with functional mitral regurgitation. Am J Cardiol. 2015; 116(2):325-31. DOI: 10.1016/j.amjcard.2015.04.025. View

Dusi V, Angelini F, Zile M, De Ferrari G . Neuromodulation devices for heart failure. Eur Heart J Suppl. 2022; 24(Suppl E):E12-E27. PMC: 9385122. DOI: 10.1093/eurheartjsupp/suac036. View

10.

Berardini A, Biagini E, Saia F, Stolfo D, Previtali M, Grigioni F . Percutaneous mitral valve repair: The last chance for symptoms improvement in advanced refractory chronic heart failure?. Int J Cardiol. 2016; 228:191-197. DOI: 10.1016/j.ijcard.2016.11.241. View

11.

Feldman T, Kar S, Elmariah S, Smart S, Trento A, Siegel R . Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5-Year Results of EVEREST II. J Am Coll Cardiol. 2016; 66(25):2844-2854. DOI: 10.1016/j.jacc.2015.10.018. View

12.

Garatti A, Castelvecchio S, Bandera F, Medda M, Menicanti L . Mitraclip procedure as a bridge therapy in a patient with heart failure listed for heart transplantation. Ann Thorac Surg. 2015; 99(5):1796-9. DOI: 10.1016/j.athoracsur.2014.07.079. View

13.

Levy W, Mozaffarian D, Linker D, Sutradhar S, Anker S, Cropp A . The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006; 113(11):1424-33. DOI: 10.1161/CIRCULATIONAHA.105.584102. View

14.

Chaudhry S, Stewart G . Advanced Heart Failure: Prevalence, Natural History, and Prognosis. Heart Fail Clin. 2016; 12(3):323-33. DOI: 10.1016/j.hfc.2016.03.001. View

15.

Rose E, Gelijns A, Moskowitz A, Heitjan D, Stevenson L, Dembitsky W . Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2002; 345(20):1435-43. DOI: 10.1056/NEJMoa012175. View

16.

Polzl G, Altenberger J, Baholli L, Beltran P, Borbely A, Comin-Colet J . Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy. Int J Cardiol. 2017; 243:389-395. DOI: 10.1016/j.ijcard.2017.05.081. View

17.

Couture P, Cloutier-Gill L, Ducharme A, Bonan R, Asgar A . MitraClip intervention as rescue therapy in cardiogenic shock: one-year follow-up. Can J Cardiol. 2014; 30(9):1108.e15-6. DOI: 10.1016/j.cjca.2014.03.045. View

18.

Nickenig G, Estevez-Loureiro R, Franzen O, Tamburino C, Vanderheyden M, Luscher T . Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011-2012 Pilot European Sentinel Registry. J Am Coll Cardiol. 2014; 64(9):875-84. DOI: 10.1016/j.jacc.2014.06.1166. View

19.

Kheifets M, Angelini F, DAscenzo F, Pidello S, Engelstein H, Bocchino P . Outcomes of Transcatheter Edge-to-Edge Repair in Degenerative vs. Functional Mitral Regurgitation. J Clin Med. 2022; 11(20). PMC: 9605257. DOI: 10.3390/jcm11206010. View

20.

Silvetti S, Nieminen M . Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysis. Int J Cardiol. 2015; 202:138-43. DOI: 10.1016/j.ijcard.2015.08.188. View